We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
QT Imaging & Olea Medical Partner to Enhance Cloud Imaging Platform
Read MoreHide Full Article
Key Takeaways
QTIH collaborates with Olea Medical to integrate analytics and visualization into its cloud platform.
Shares of QTIH jumped 8.3% after the news and have outperformed the industry and S&P 500 over six months.
The integration supports multimodality breast imaging, advanced analytics and cloud delivery.
QT Imaging Holdings, Inc. (QTIH - Free Report) recently announced a collaboration with Olea Medical aimed at enhancing visualization, quantitative analytics and multimodality integration across its cloud imaging platform. Olea Medical brings established quantitative analytics and multimodality capabilities spanning magnetic resonance (MR), computed tomography (CT) and ultrasound (US) imaging.
Under the collaboration, Olea Medical’s advanced visualization, quantitative analytics and AI-ready imaging capabilities will be integrated into QT Imaging’s cloud-based SaaS platform. The integration is expected to enhance clinical interpretation, support research workflows and enable advanced quantitative imaging analysis. This initiative builds on QT Imaging’s existing cloud infrastructure and will be deployed through the InteleShare platform, which serves as the enterprise PACS and cloud backbone for the company’s clinical and research implementations.
Per management, the collaboration with Olea Medical enhances QT Imaging’s cloud platform by expanding its clinical visualization and analytical functionality. Combined with the enterprise-scale delivery infrastructure being implemented, the collaboration enhances QT Imaging’s ability to deliver secure, high-performance cloud-based imaging with advanced analytics, supporting both clinical care and research use cases.
Likely Trend of QTIH Stock Following the News
Following the announcement, shares of QTIH gained 8.3% at yesterday’s closing. Over the past six months, shares of the company have climbed 14% compared with the industry’s 5.6% growth and the S&P 500’s 11.4% rise.
In the long run, by combining innovative acoustic imaging with Olea Medical’s trusted, clinically validated software, QT Imaging strengthens its value proposition to providers and researchers, positioning the company to participate in the evolution of data-driven, quantitative breast imaging. The partnership supports broader multimodality integration, enabling QT Imaging to position its solution more competitively within existing breast imaging workflows. The collaboration strengthens the company’s plan to offer a single, cloud-based imaging platform that connects its new acoustic imaging technology with standard radiology tools and advanced analytics by leveraging a trusted, established imaging software partner.
QTIH currently has a market capitalization of $71.55 million.
Image Source: Zacks Investment Research
More on the Collaboration
QT Imaging enables clinical interpretation of its imaging data within its existing infrastructure by integrating Olea Medical’s validated visualization and quantitative analytics technologies. The combined platform supports a scalable, multimodality breast imaging workflow, bringing together mammography, digital breast tomosynthesis, ultrasound, MR imaging and QT imaging studies across the continuum of breast care. Advanced quantitative analytics, segmentation and volumetric analysis are expected to enhance lesion characterization, improve diagnostic confidence and increase clinical efficiency. Secure, network-enabled access further supports multi-institutional collaboration, centralized research operations and standardized execution of clinical trials.
The collaboration is aligned with QT Imaging’s strategic roadmap to drive broader adoption of its Breast Acoustic CT technology while enabling future AI- and machine learning-based analytics through its cloud infrastructure. The company will offer the QT Imaging Olea Vision software, a customizable 3D and 4D DICOM viewer with user-defined hanging protocols. The software allows smooth navigation across DICOM series, advanced 3D viewing and image manipulation capabilities and incorporates subtraction tools to enhance diagnostic assessment.
Dr. Faycal Djeridane, Founder and CEO of Olea Medical, stated that the collaboration with QT Imaging extends Olea Medical’s advanced visualization and quantitative imaging capabilities into next-generation breast imaging solutions, reflecting a shared focus on clinically relevant innovation, multimodality integration and quantitative imaging. Overall, this collaboration supports QT Imaging’s goal of delivering patient-centered imaging solutions while expanding its addressable market across clinical care and research settings and positions the company for long-term growth, broader clinical acceptance and increased competitiveness in the medical imaging landscape.
Industry Prospects Favoring the Market
Going by data provided by Precedence Research, the artificial intelligence in the breast imaging market is anticipated to be valued at $666.9 million in 2026 and is expected to witness a CAGR of 15.9% through 2035. Factors like high breast cancer incidence and prevalence rate, a favorable framework for reimbursement for breast cancer diagnosis, increased breast cancer awareness and early detection, growing health insurance and an increasing aging population are driving the market’s growth.
Other News
QT Imaging announced a distribution agreement with Al Naghi Medical Co. for its QTI Breast Acoustic CT scanners and QTI Cloud Platform in the United Arab Emirates. The agreement provides for minimum committed orders totaling 43 scanners between 2026 and 2028, representing more than $24 million in anticipated revenues and marking a meaningful expansion of the company’s international footprint. The partnership leverages NMC’s established regional distribution capabilities and positions QT Imaging to address a market with a high incidence of breast cancer. This agreement supports QT Imaging’s commercialization strategy while advancing the adoption of its cloud-enabled imaging and analytics platform in a key growth market.
Veracyte, sporting a Zacks Rank #1 (Strong Buy) at present, reported third-quarter 2025 adjusted earnings per share (EPS) of 51 cents, which surpassed the Zacks Consensus Estimate by 59.4%. Revenues of $131.8 million beat the Zacks Consensus Estimate by 5.5%. You can see the complete list of today’s Zacks #1 Rank stocks here.
VCYT has an estimated earnings recession rate of 3% for 2026 compared with the industry’s 17.7% rise. The company beat earnings estimates in the trailing four quarters, the average surprise being 45.1%.
AtriCure, currently sporting a Zacks Rank #1, reported a third-quarter 2025 adjusted loss of 1 cent per share, narrower than the Zacks Consensus Estimate by 90.9%. Revenues of $134.3 million beat the Zacks Consensus Estimate by 2.1%.
ATRC has an estimated earnings growth rate of 91.7% for 2026 compared with the industry’s 16.9% rise. The company beat earnings estimates in the trailing four quarters, the average surprise being 67.1%.
Boston Scientific, currently carrying a Zacks Rank #2 (Buy), reported a third-quarter 2025 adjusted EPS of 75 cents, which surpassed the Zacks Consensus Estimate by 5.6%. Revenues of $5.07 billion beat the Zacks Consensus Estimate by 1.9%.
BSX has an estimated long-term earnings growth rate of 16.4% compared with the industry’s 13.1% growth. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 7.4%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
QT Imaging & Olea Medical Partner to Enhance Cloud Imaging Platform
Key Takeaways
QT Imaging Holdings, Inc. (QTIH - Free Report) recently announced a collaboration with Olea Medical aimed at enhancing visualization, quantitative analytics and multimodality integration across its cloud imaging platform. Olea Medical brings established quantitative analytics and multimodality capabilities spanning magnetic resonance (MR), computed tomography (CT) and ultrasound (US) imaging.
Under the collaboration, Olea Medical’s advanced visualization, quantitative analytics and AI-ready imaging capabilities will be integrated into QT Imaging’s cloud-based SaaS platform. The integration is expected to enhance clinical interpretation, support research workflows and enable advanced quantitative imaging analysis. This initiative builds on QT Imaging’s existing cloud infrastructure and will be deployed through the InteleShare platform, which serves as the enterprise PACS and cloud backbone for the company’s clinical and research implementations.
Per management, the collaboration with Olea Medical enhances QT Imaging’s cloud platform by expanding its clinical visualization and analytical functionality. Combined with the enterprise-scale delivery infrastructure being implemented, the collaboration enhances QT Imaging’s ability to deliver secure, high-performance cloud-based imaging with advanced analytics, supporting both clinical care and research use cases.
Likely Trend of QTIH Stock Following the News
Following the announcement, shares of QTIH gained 8.3% at yesterday’s closing. Over the past six months, shares of the company have climbed 14% compared with the industry’s 5.6% growth and the S&P 500’s 11.4% rise.
In the long run, by combining innovative acoustic imaging with Olea Medical’s trusted, clinically validated software, QT Imaging strengthens its value proposition to providers and researchers, positioning the company to participate in the evolution of data-driven, quantitative breast imaging. The partnership supports broader multimodality integration, enabling QT Imaging to position its solution more competitively within existing breast imaging workflows. The collaboration strengthens the company’s plan to offer a single, cloud-based imaging platform that connects its new acoustic imaging technology with standard radiology tools and advanced analytics by leveraging a trusted, established imaging software partner.
QTIH currently has a market capitalization of $71.55 million.
Image Source: Zacks Investment Research
More on the Collaboration
QT Imaging enables clinical interpretation of its imaging data within its existing infrastructure by integrating Olea Medical’s validated visualization and quantitative analytics technologies. The combined platform supports a scalable, multimodality breast imaging workflow, bringing together mammography, digital breast tomosynthesis, ultrasound, MR imaging and QT imaging studies across the continuum of breast care. Advanced quantitative analytics, segmentation and volumetric analysis are expected to enhance lesion characterization, improve diagnostic confidence and increase clinical efficiency. Secure, network-enabled access further supports multi-institutional collaboration, centralized research operations and standardized execution of clinical trials.
The collaboration is aligned with QT Imaging’s strategic roadmap to drive broader adoption of its Breast Acoustic CT technology while enabling future AI- and machine learning-based analytics through its cloud infrastructure. The company will offer the QT Imaging Olea Vision software, a customizable 3D and 4D DICOM viewer with user-defined hanging protocols. The software allows smooth navigation across DICOM series, advanced 3D viewing and image manipulation capabilities and incorporates subtraction tools to enhance diagnostic assessment.
Dr. Faycal Djeridane, Founder and CEO of Olea Medical, stated that the collaboration with QT Imaging extends Olea Medical’s advanced visualization and quantitative imaging capabilities into next-generation breast imaging solutions, reflecting a shared focus on clinically relevant innovation, multimodality integration and quantitative imaging. Overall, this collaboration supports QT Imaging’s goal of delivering patient-centered imaging solutions while expanding its addressable market across clinical care and research settings and positions the company for long-term growth, broader clinical acceptance and increased competitiveness in the medical imaging landscape.
Industry Prospects Favoring the Market
Going by data provided by Precedence Research, the artificial intelligence in the breast imaging market is anticipated to be valued at $666.9 million in 2026 and is expected to witness a CAGR of 15.9% through 2035. Factors like high breast cancer incidence and prevalence rate, a favorable framework for reimbursement for breast cancer diagnosis, increased breast cancer awareness and early detection, growing health insurance and an increasing aging population are driving the market’s growth.
Other News
QT Imaging announced a distribution agreement with Al Naghi Medical Co. for its QTI Breast Acoustic CT scanners and QTI Cloud Platform in the United Arab Emirates. The agreement provides for minimum committed orders totaling 43 scanners between 2026 and 2028, representing more than $24 million in anticipated revenues and marking a meaningful expansion of the company’s international footprint. The partnership leverages NMC’s established regional distribution capabilities and positions QT Imaging to address a market with a high incidence of breast cancer. This agreement supports QT Imaging’s commercialization strategy while advancing the adoption of its cloud-enabled imaging and analytics platform in a key growth market.
QT Imaging Holdings, Inc. Price
QT Imaging Holdings, Inc. price | QT Imaging Holdings, Inc. Quote
QTIH’s Zacks Rank & Key Picks
Currently, QTIH carries a Zacks Rank #3 (Hold).
Some top-ranked stocks from the broader medical space are Veracyte (VCYT - Free Report) , AtriCure (ATRC - Free Report) and Boston Scientific (BSX - Free Report) .
Veracyte, sporting a Zacks Rank #1 (Strong Buy) at present, reported third-quarter 2025 adjusted earnings per share (EPS) of 51 cents, which surpassed the Zacks Consensus Estimate by 59.4%. Revenues of $131.8 million beat the Zacks Consensus Estimate by 5.5%. You can see the complete list of today’s Zacks #1 Rank stocks here.
VCYT has an estimated earnings recession rate of 3% for 2026 compared with the industry’s 17.7% rise. The company beat earnings estimates in the trailing four quarters, the average surprise being 45.1%.
AtriCure, currently sporting a Zacks Rank #1, reported a third-quarter 2025 adjusted loss of 1 cent per share, narrower than the Zacks Consensus Estimate by 90.9%. Revenues of $134.3 million beat the Zacks Consensus Estimate by 2.1%.
ATRC has an estimated earnings growth rate of 91.7% for 2026 compared with the industry’s 16.9% rise. The company beat earnings estimates in the trailing four quarters, the average surprise being 67.1%.
Boston Scientific, currently carrying a Zacks Rank #2 (Buy), reported a third-quarter 2025 adjusted EPS of 75 cents, which surpassed the Zacks Consensus Estimate by 5.6%. Revenues of $5.07 billion beat the Zacks Consensus Estimate by 1.9%.
BSX has an estimated long-term earnings growth rate of 16.4% compared with the industry’s 13.1% growth. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 7.4%.